Cargando…
The clinical aspects of pituitary tumour genetics
BACKGROUND: Pituitary tumours are usually benign and relatively common intracranial tumours, with under- and overexpression of pituitary hormones and local mass effects causing considerable morbidity and increased mortality. While most pituitary tumours are sporadic, around 5% of the cases arise in...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016799/ https://www.ncbi.nlm.nih.gov/pubmed/33543431 http://dx.doi.org/10.1007/s12020-021-02633-0 |
_version_ | 1783673928117387264 |
---|---|
author | Dénes, Judit Korbonits, Márta |
author_facet | Dénes, Judit Korbonits, Márta |
author_sort | Dénes, Judit |
collection | PubMed |
description | BACKGROUND: Pituitary tumours are usually benign and relatively common intracranial tumours, with under- and overexpression of pituitary hormones and local mass effects causing considerable morbidity and increased mortality. While most pituitary tumours are sporadic, around 5% of the cases arise in a familial setting, either isolated [familial isolated pituitary adenoma, related to AIP or X-linked acrogigantism], or in a syndromic disorder, such as multiple endocrine neoplasia type 1 or 4, Carney complex, McCune–Albright syndrome, phaeochromocytoma/paraganglioma with pituitary adenoma, DICER1 syndrome, Lynch syndrome, and USP8-related syndrome. Genetically determined pituitary tumours usually present at younger age and show aggressive behaviour, and are often resistant to different treatment modalities. SUBJECT: In this practical summary, we take a practical approach: which genetic syndromes should be considered in case of different presentation, such as tumour type, family history, age of onset and additional clinical features of the patient. CONCLUSION: The identification of the causative mutation allows genetic and clinical screening of relatives at risk, resulting in earlier diagnosis, a better therapeutic response and ultimately to better long-term outcomes. |
format | Online Article Text |
id | pubmed-8016799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-80167992021-04-16 The clinical aspects of pituitary tumour genetics Dénes, Judit Korbonits, Márta Endocrine Review BACKGROUND: Pituitary tumours are usually benign and relatively common intracranial tumours, with under- and overexpression of pituitary hormones and local mass effects causing considerable morbidity and increased mortality. While most pituitary tumours are sporadic, around 5% of the cases arise in a familial setting, either isolated [familial isolated pituitary adenoma, related to AIP or X-linked acrogigantism], or in a syndromic disorder, such as multiple endocrine neoplasia type 1 or 4, Carney complex, McCune–Albright syndrome, phaeochromocytoma/paraganglioma with pituitary adenoma, DICER1 syndrome, Lynch syndrome, and USP8-related syndrome. Genetically determined pituitary tumours usually present at younger age and show aggressive behaviour, and are often resistant to different treatment modalities. SUBJECT: In this practical summary, we take a practical approach: which genetic syndromes should be considered in case of different presentation, such as tumour type, family history, age of onset and additional clinical features of the patient. CONCLUSION: The identification of the causative mutation allows genetic and clinical screening of relatives at risk, resulting in earlier diagnosis, a better therapeutic response and ultimately to better long-term outcomes. Springer US 2021-02-04 2021 /pmc/articles/PMC8016799/ /pubmed/33543431 http://dx.doi.org/10.1007/s12020-021-02633-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Dénes, Judit Korbonits, Márta The clinical aspects of pituitary tumour genetics |
title | The clinical aspects of pituitary tumour genetics |
title_full | The clinical aspects of pituitary tumour genetics |
title_fullStr | The clinical aspects of pituitary tumour genetics |
title_full_unstemmed | The clinical aspects of pituitary tumour genetics |
title_short | The clinical aspects of pituitary tumour genetics |
title_sort | clinical aspects of pituitary tumour genetics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016799/ https://www.ncbi.nlm.nih.gov/pubmed/33543431 http://dx.doi.org/10.1007/s12020-021-02633-0 |
work_keys_str_mv | AT denesjudit theclinicalaspectsofpituitarytumourgenetics AT korbonitsmarta theclinicalaspectsofpituitarytumourgenetics AT denesjudit clinicalaspectsofpituitarytumourgenetics AT korbonitsmarta clinicalaspectsofpituitarytumourgenetics |